E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at least two prior lines of treatment. |
Patient(e) présentant une maladie inflammatoire mal classée, impliquant au moins deux organes dont au moins la peau, et un des suivants : ganglions lymphatiques, système hématopoïétique, articulations, appareil digestif. La maladie a été résistante à au moins deux lignes de traitement. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients presenting inflammatory non classified disease, resistant to prior treatment |
patients présentant une maladie inflammatoire non classée, sévère et résistante |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10062249 |
E.1.2 | Term | Skin inflammation |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this study is to evaluate the efficacy of targeted treatments in patients displaying a non-classified, severe and resistant inflammatory disease. Targeted treatments for each patient will have been selected through an algorithm based on molecular analysis of specific altered inflammatory signaling pathway. |
L'objectif principal de cette étude est d'évaluer l'efficacité de traitements ciblés chez des patients présentant une maladie inflammatoire non classée, sévère et résistante. Le traitement ciblé pour chaque patient aura été sélectionné grâce à un algorithme basé sur l'analyse moléculaire de la voie de signalisation inflammatoire spécifique. |
|
E.2.2 | Secondary objectives of the trial |
(a) to analyze the safety at several time points of targeted treatment selected through molecular based algorithm, (b) to analyze the other clinical global and cutaneous efficacy parameters (c) to study whether the treatment selected has been able to inhibit the culprit pathway using mRNA analysis before and after treatment as well as serum markers before and after treatment (d) to assess whether full RNA sequencing can depict in lesional skin, overexpressed pathway(s) that the targeted RNA set has not detected |
(a) analyser la tolérance à plusieurs temps du traitement sélectionné (b) analyser les autres paramètres d’efficacité cliniques globaux et d'efficacité cutanée. (c) vérifier que le traitement sélectionné a permis d’inhiber la voie moléculaire considérée comme responsable. (d) évaluer si le séquençage complet de l'ARN (« ARN seq ») peut dépister dans la peau lésée et saine, une ou des voie (s) surexprimée (s) que l’analyse antérieure ciblées n'aurait pas détecté |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Patients (men or women) aged 18 years old and over -Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. Skin involvement is mandatory in order to be able to compare involved and non involved tissue -Signed informed consent
The disease should be considered as non-classified despite classical and adapted investigations and evaluation through expert committee meeting. The disease alters significantly quality of life using SF36 assessment : score less than 30. The disease has been resistant to at least two prior lines of treatment.
|
-Patient (homme ou femme) âgé de 18 ans ou plus -Patient(e) présentant une maladie inflammatoire mal classée, impliquant au moins deux organes dont au moins la peau, et un des suivants : ganglions lymphatiques, système hématopoïétique, articulations, appareil digestif -Patient(e) ayant donné son consentement éclairé et écrit pour participer à l'étude
La maladie est considérée comme une pathologie inflammatoire multi organes complexe après des investigations habituelles et une évaluation par un Comité d’experts. La maladie altère de façon significative la qualité de vie en utilisant le questionnaire SF-36 (score < 30). La maladie a été résistante à au moins deux lignes de traitement.
|
|
E.4 | Principal exclusion criteria |
-Patients presenting disease which is not featured by lesional and healthy skin areas, easy to biopsy -Patients refusing biopsies -Pregnancy -Women of child-bearing potential unable to receive highly efficient contraception such as combined oral contraceptives, intra-uterine disposals, hormonal implants or the use of male condoms recommended in case of unstable or irregular partner or as a replacement method for transient unacessebility to hormonal method -Breastfeeding -Patients presenting disease needing urgent therapeutic measures -Patients without health insurance or social security -Patients under legal protection -Participation in another interventional trial -Patients unable to respect the wash out delay of previously taken medications before inclusion time : *Hydroxychloroquine (wash out period = 30 days) *Chloroquine (wash out period = 7 days) *Colchicine (wash out period = 7 days) *Methotrexate (wash out period = 7 days) *Ciclosporine (wash out period = 14 days) *Azathioprine (wash out period = 14 days) *Mycophenolate mofetil (wash out period = 14 days) *Disulone (wash out period = 7 days) *Corticosteroids (=prednisone, prednisolone, dexamethasone, methylprednisolone) (wash out period = 7 days) -Patients with contra-indications to treatments: Severe or active infections including tuberculosis
Importantly, in this study, the treatment will be selected by a committee depending on three criteria (cf Design of the trial: Interpretation of the data) including contra indications of the patients to the drugs. Therefore, contra indicated medications cannot be selected by the committee in view of protocol participation.
|
-Patient(e) dont la maladie ne comporte pas une zone de peau lésée cutanée et une zone de peau saine faciles à biopsier -Patient(e) refusant les biopsies -Femme enceinte ou allaitante -Les femmes en âge de procréer n’utilisant pas un moyen de contraception efficace, tels que les contraceptifs oraux, les dispositifs intra-utérins et les implants hormonaux ou l’usage du préservatif masculin recommandé en cas d’absence de partenaire stable ou en méthode de remplacement à garder à disposition en cas d’inaccessibilité ponctuelle ou de défaut d’observance d’une méthode hormonale. -Patient(e) présentant une maladie nécessitant des soins médicaux d’urgence -Patient(e) ne disposant pas d’un régime de sécurité sociale -Patient(e) sous protection juridique -Patient(e) participant à un autre essai interventionnel -Patient(e) ne pouvant pas, au moment de son inclusion dans l’étude, respecter les délais de wash-out par rapport aux traitements pris précédemment: *Hydroxychloroquine (période de wash-out = 30 jours) *Chloroquine (période de wash-out = 7 jours) *Colchicine (période de wash-out = 7 jours) *Méthotrexate (période de wash-out = 7 jours) *Ciclosporine (période de wash-out = 14 jours) *Azathioprine (période de wash-out = 14 jours) * Mycophenolate mofetil (période de wash-out = 14 jours) *Disulone (période de wash-out = 7 jours) *Corticosteroïdes (=prednisone, prednisolone, dexaméthasone, méthylprednisolone) (période de wash-out = 7 jours) -Patient(e) présentant des contre-indications aux traitements: Infections sévères ou actives dont la tuberculose
Important : dans cette étude, le traitement sera sélectionné par un comité notamment en prenant en compte les contre-indications des patients aux traitements évalués. Par conséquent, un patient ne pourra recevoir un traitement pour lequel il présente une contre-indication.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Response will be assessed at month 6 with a composite endpoint defined as improvement of at least 2 of the 3 following parameters: - 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10), - and/or 50% improvement of cutaneous activity assessed by the involved skin surface area, - and/or 50% decrease or nomalisation of biological markers of inflammation (either CRP, ESR or fibrin). An independent adjudication committee blinded to the treatment received will review primary endpoint for all patients based on clinical files and standardized photographs, to validate the response.
|
La réponse sera évaluée au 6ième mois avec un critère composite défini comme l'amélioration d'au moins 2 des 3 paramètres suivants : - Amélioration de 50% de l'activité systémique évaluée par le clinicien selon une échelle visuelle analogique (0-10), - et / ou 50% d'amélioration de la surface cutanée concernée, - et / ou une diminution de 50% ou une normalisation des marqueurs biologiques de l'inflammation (CRP, VS ou fibrinogène). Un comité indépendant, en insu du traitement reçu, examinera le critère d'évaluation principal pour tous les patients afin de valider la réponse, à l’aide des dossiers cliniques et des clichés standardisés
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
a) Adverse events (mainly infections, liver, kidney and blood cell count toxicities) of targeted treatment selected through molecular analysis during patient follow up using the CTCAE classification b) The following parameters will be assessed at various time-points and compared with baseline values: Physician Assessment of systemic activity (PGA) at M1, M3, M6 to M12 Physician Assessment of cutaneous activity (PGA) at M1, M3, M6 to M12 Biological markers of inflammation (CRP, ESR and fibrin) at M1, M3, M6 to M12 BILAG, CLASI, SF36 and SRI score at M3, M6 to M12 c) Reduction of the selected mRNA in skin and peripheral blood at M1, M3, M6 and M12 d) Reduction of the selected cytokine in serum at M1, M3, M6 and M12 e) RNA sequencing analysis in lesional versus non lesional skin at M0 with bioinformatics analysis f) Ability using molecular tools to better classify “atypical disease” into a taxonomy of standard disease groups g) Determine whether PBL and serum changes are informative in the design and/or the response of therapies for inflammatory diseases
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |